CLINICAL
TRIALS
Studies Open to Accrual (March 2009)
ACUTE/RECENT
INFECTION
ACTG
A5217 - "A Randomized Study of Treatment with Tenofovir
DF, Emtricitabine, and Lopinavir/Ritonavir versus no Therapy in Newly Infected
HIV-1 Infected Subjects to Determine Whether Potent Antiretroviral Therapy
Alters the Virologic Setpoint"
ACTG A5257 - "A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1 Infected Volunteers"
ACTG A5262 - "A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects"
EXPERIENCED
PATIENTS
ACTG
A5241 - "The Optimized Treatment that Includes
or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-Infected
Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen"
ACTG A5244- "A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification with a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia below 50 copies/mL in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens."
OPPORTUNISTIC
INFECTIONS/COMPLICATIONS/MISC
ACTG
A5232 [Vaccine Response/HCV/HIV]
- "Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by
Identifying Determinants of Responsiveness: A Pilot Study"
ACTG A5235 [Neurocognitive Impairment] - "Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment"
ACTG A5240 [HPV/Women] - "A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females"
ACTG A5247 [Zostavax] - "A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART with Conserved Immune Function"
COMIRB
04-1101 - "Sex- and Disease-Dependent Nucleoside Analog Toxicity."